Chinese technology companies are increasingly important and dynamic international actors. They are making critical contributions in a range of areas, from cutting edge research to enabling connectivity for developing countries. Yet, their rapid expansion and growing influence also bring a range of strategic and policy challenges. The Australian Strategic Policy Institute’s International Cyber Policy Centre has created a public database to map the global expansion of 12 key Chinese tech companies working across the telecommunications, internet & biotech sectors. It’s a tool for journalists, researchers, NGOs, policymakers and the interested public to better understand the enormous scale, complexity and increasing reach of some of China’s tech giants. On this website you’ll find:
People with incurable melanomas and brain or breast cancers are to get injections of tumour-fighting viruses.
The trial will test the safety of a virus that has been engineered to shrink tumours – an approach that holds promise for a range of cancers, including deadly brain tumours.
Prosthetics have advanced drastically in recent years. The technology’s potential has even inspired many, like Elon Musk, to ask whether we may be living as “cyborgs” in the not-too-far future. For Johnny Matheny of Port Richey, Florida, that future is now. Matheny, who lost his arm to cancer in 2005, has recently become the first person to live with an advanced mind-controlled robotic arm. He received the arm in December and will be spending the next year testing it out.
The arm was developed by Johns Hopkins Applied Physics Lab as part of their program Revolutionizing Prosthetics. The aim of the program, which is funded by the Defense Advanced Research Projects Agency (DARPA), is to create prosthetics that are controlled by neural activity in the brain to restore motor function to where it feels entirely natural. The program is specifically working on prosthetics for upper-arm amputee patients. While this particular arm has been demoed before, Matheny will be the first person to actually live with the prosthesis. The program does hope to have more patients take the tech for a longterm test run, though.
While the prosthetic device is impressive, it’s not a limitless, all-powerful robot arm. Matheney won’t be able to get the arm wet and is not allowed to drive while wearing it. Keeping a few rules in mind, Matheney will otherwise be free to push the tech to the edge of its capabilities, truly exploring what it can do.
Some 360,000 children a year in three African countries will receive the world’s first malaria vaccine as part of a large-scale pilot project, the World Health Organization (WHO) said Tuesday.
Malawi has started vaccinating children under two years of age and Kenya and Ghana will begin using the vaccine in the coming weeks, with health ministries in these countries deciding where it will be used, the WHO said.
A state-of-the-art brain-machine interface created by UC San Francisco neuroscientists can generate natural-sounding synthetic speech by using brain activity to control a virtual vocal tract—an anatomically detailed computer simulation including the lips, jaw, tongue, and larynx. The study was conducted in research participants with intact speech, but the technology could one day restore the voices of people who have lost the ability to speak due to paralysis and other forms of neurological damage.
Stroke, traumatic brain injury, and neurodegenerative diseases such as Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) often result in an irreversible loss of the ability to speak. Some people with severe speech disabilities learn to spell out their thoughts letter-by-letter using assistive devices that track very small eye or facial muscle movements. However, producing text or synthesized speech with such devices is laborious, error-prone, and painfully slow, typically permitting a maximum of 10 words per minute, compared to the 100–150 words per minute of natural speech.
The new system being developed in the laboratory of Edward Chang, MD—described April 24, 2019 in Nature—demonstrates that it is possible to create a synthesized version of a person’s voice that can be controlled by the activity of their brain’s speech centers. In the future, this approach could not only restore fluent communication to individuals with severe speech disability, the authors say, but could also reproduce some of the musicality of the human voice that conveys the speaker’s emotions and personality.
Ovarian cancer is usually diagnosed only after it has reached an advanced stage, with many tumors spread throughout the abdomen. Most patients undergo surgery to remove as many of these tumors as possible, but because some are so small and widespread, it is difficult to eradicate all of them.
Researchers at MIT, working with surgeons and oncologists at Massachusetts General Hospital (MGH), have now developed a way to improve the accuracy of this surgery, called debulking. Using a novel fluorescence imaging system, they were able to find and remove tumors as small as 0.3 millimeters—smaller than a poppy seed—during surgery in mice. Mice that underwent this type of image-guided surgery survived 40 percent longer than those who had tumors removed without the guided system.
“What’s nice about this system is that it allows for real-time information about the size, depth, and distribution of tumors,” says Angela Belcher, the James Mason Crafts Professor of Biological Engineering and Materials Science at MIT, a member of the Koch Institute for Integrative Cancer Research, and the recently appointed head of MIT’s Department of Biological Engineering.
Bioengineers at Boston Children’s Hospital report the first demonstration of a robot able to navigate autonomously inside the body. In an animal model of cardiac valve repair, the team programmed a robotic catheter to find its way along the walls of a beating, blood-filled heart to a leaky valve—without a surgeon’s guidance. They report their work today in Science Robotics.
Surgeons have used robots operated by joysticks for more than a decade, and teams have shown that tiny robots can be steered through the body by external forces such as magnetism. However, senior investigator Pierre Dupont, Ph.D., chief of Pediatric Cardiac Bioengineering at Boston Children’s, says that to his knowledge, this is the first report of the equivalent of a self-driving car navigating to a desired destination inside the body.
Dupont envisions autonomous robots assisting surgeons in complex operations, reducing fatigue and freeing surgeons to focus on the most difficult maneuvers, improving outcomes.
A special focus on rogue proteins may hold future promise in stopping the progression of nerve cell destruction in people who have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia.
ALS, a rare but devastating disorder that’s also known as Lou Gehrig’s disease, attacks the body’s nerve cells, resulting in progressive muscle weakness as the neurons degenerate over time. There is no cure. People with ALS eventually lose their strength and the ability to move their arms, legs and body.
About a third of those with ALS also develop frontotemporal dementia (FTD), a destruction of neurons in the brain that causes profound personality changes and disability. The two diseases are similar in both pathology and genetics. FTD tends to affect people earlier than Alzheimer’s disease, the most common type of dementia.
Using human cancer cells, tumor and blood samples from cancer patients, researchers at Johns Hopkins Medicine have uncovered the role of a neurotransmitter in the spread of aggressive cancers. Neurotransmitters are chemical “messengers” that transmit impulses from neurons to other target cells.
The work, described in the April 9 issue of the journal Cell Reports, found that this neurotransmitter, called N-acetyl-aspartyl-glutamate (NAAG) NAAG is more abundant in cancers with a tendency to grow and spread rapidly—or so-called higher grade cancers—than in lower grade tumors, making it a potential marker for tumor progression or regression during cancer therapy, the researchers say. The experiments also demonstrated that NAAG is a source of glutamate, a chemical that cancer cells use as building blocks to survive, in tumors that express an enzyme called glutamate carboxypeptidase II (GCPII). The group also discovered that stopping the GCPII from being active by using a drug called 2-PMPA to treat human ovarian tumors implanted in ovaries of mice, reduced tumor weights and glutamate concentrations.
